SLS 18RS-123 ENGROSSED

2018 Regular Session

SENATE BILL NO. 28

BY SENATOR MILLS

HEALTH CARE. Provides relative to veterinarians. (8/1/18)

1	AN ACT
2	To enact R.S. 37:1251(D) and R.S. 40:978(F)(3) and 978.3(E), relative to veterinarians; to
3	exempt veterinarians and certain manufacturers from disclosure of prescription drug
4	price information provisions; to exempt veterinarians from accessing the prescription
5	monitoring program prior to prescribing an opioid; to exempt veterinarians from
6	continuing education requirements for prescribers of controlled dangerous
7	substances; and to provide for related matters.
8	Be it enacted by the Legislature of Louisiana:
9	Section 1. R.S. 37:1251(D) is hereby enacted to read as follows:
10	§1251. Disclosure of prescription drug price information
11	* * *
12	D. The provisions of this Section shall not apply to veterinarians or
13	pharmaceutical marketers who engage in any form of prescription drug
14	marketing directly to a prescriber, his designee, or any member of his staff
15	regarding prescription drugs manufactured exclusively for nonhuman
16	consumption.
17	Section 2. R.S. 40:978(F)(3) and 978.3(E) are hereby enacted to read as follows:

SLS 18RS-123 ENGROSSED
SB NO. 28

1 §978. Prescriptions 2 3 F. 4 (3) The provisions of this Subsection shall not apply to individuals 5 licensed by the Louisiana Board of Veterinary Medicine. 6 7 8 §978.3. Continuing education for the prescribing of controlled substances 9 10 E. The provisions of this Section shall not apply to individuals licensed 11 by the Louisiana Board of Veterinary Medicine.

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Christine Arbo Peck.

DIGEST 2018 Regular Session

Mills

SB 28 Engrossed

<u>Present law</u> provides that pharmaceutical manufacturers who engage in marketing directly to a prescriber may inform the prescribers of an internet website containing prescription drug price information.

<u>Proposed law</u> exempts veterinarians and certain pharmaceutical marketers of prescription drugs manufactured exclusively for nonhuman consumption from the provisions established in <u>present law</u> regarding disclosure of prescription drug price information.

<u>Present law</u> requires prescribers to access the prescription drug monitoring program prior to initially prescribing an opioid and every 90 days if the course of treatment continues.

<u>Proposed law</u> exempts veterinarians from accessing the prescription monitoring program prior to prescribing an opioid and every 90 days if the course of treatment continues.

<u>Present law</u> requires prescribers of controlled dangerous substances to obtain three credit hours of continuing education on drug diversion training, best practice prescribing of controlled substances, appropriate treatment for addiction, and other matters deemed relevant by their respective licensing board.

<u>Proposed law</u> exempts veterinarians from continuing education requirements for prescribers of controlled dangerous substances.

Effective August 1, 2018.

(Adds R.S. 37:1251(D) and R.S. 40:978(F)(3) and 978.3(E))